FUTURE-SUPER tested a defined subtype-linked treatment strategy in advanced TNBC. The pooled phase 2 PFS comparison was positive; the current registry does not establish availability.
Single-centre, open-label phase 2 study at Fudan University Shanghai Cancer Center. Participants were women aged 18-70, ECOG 0-1, with untreated metastatic or recurrent TNBC. Five cohorts combined a Fudan subtype classification with genomic biomarkers. Within that strategy, 139 participants were randomised to matched additions to nab-paclitaxel (69) or nab-paclitaxel alone (70). This is a different classifier from Lehmann TNBCtype-4.
The primary comparison was investigator-assessed progression-free survival in the pooled intention-to-treat groups. At the 31 May 2023 cutoff, median follow-up was 22.5 months (interquartile range 15.2-29.0). It tested a package of classification, matching rules and regimens; it did not separately establish each component's effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
139 enrolled.
95 percent confidence interval 8.6-15.2 · 95 percent confidence interval 4.0-6.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Investigator-assessed progression-free survival, pooled intention-to-treat comparisonprimary | Subtype/genomic-marker strategy plus nab-paclitaxel | 69 | 11.3 months | 0.44 (0.3 to 0.65) | <0.0001 | link |
| Nab-paclitaxel alone | 70 | 5.8 months |
Shares Yi-Zhou Jiang, Zhi-Ming Shao, Triple-negative breast cancer (TNBC).
Shares Triple-negative breast cancer (TNBC) and the tag education-audit.
Shares Triple-negative breast cancer (TNBC) and the tag education-audit.
Shares Pyrotinib, Camrelizumab.
Shares Yi-Zhou Jiang, Zhi-Ming Shao, Triple-negative breast cancer (TNBC).
Shares Camrelizumab, Nab-paclitaxel.
Shares TNBC molecular subtyping, Triple-negative breast cancer (TNBC).
Shares TNBC molecular subtyping, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/